Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy—the P-SELECT trial (WJOG10617G)—a randomised phase II trial by the West Japan Oncology Group

BACKGROUND: Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was developed to improve the therapeutic index of taxane treatment. However, the ABSO...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:BMC Cancer
Main Authors: Hirata, Kenro, Hamamoto, Yasuo, Ando, Masahiko, Imamura, Chiyo K., Yoshimura, Kenichi, Yamazaki, Kentaro, Hironaka, Shuichi, Muro, Kei
Format: Artigo
Sprog:Inglês
Udgivet: BioMed Central 2020
Fag:
Study Protocol
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7291575/
https://ncbi.nlm.nih.gov/pubmed/32532230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07047-1
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker